Journal of cardiothoracic and vascular anesthesia
-
J. Cardiothorac. Vasc. Anesth. · Jun 2008
Randomized Controlled Trial Comparative StudyMyocardial metabolism altered by ischemic preconditioning and enflurane in off-pump coronary artery surgery.
During off-pump coronary artery bypass (OPCAB) surgery, the heart is subjected to ischemia and reperfusion. The authors hypothesized that the volatile anesthetics are as effective as ischemic preconditioning (IPC) in preserving myocardial function during off-pump cardiac surgery, and this effect is because of multiple mechanisms of action. Therefore, the effects of enflurane with its calcium inhibition and antioxidative properties were compared with mechanical IPC in preserving myocardial cellular markers. ⋯ Coronary occlusion during OPCAB surgery results in increased production of ischemia-related metabolic products. The application of methods such as IPC or volatile anesthesia appears to reduce the metabolic deficit, free-radical production, and physiologic changes.
-
J. Cardiothorac. Vasc. Anesth. · Jun 2008
Comparative Study Controlled Clinical TrialMonocyte activation in on-pump versus off-pump coronary artery bypass surgery.
Monocyte activation plays a key role in amplifying both inflammatory and coagulopathic sequelae in patients undergoing on-pump coronary artery bypass graft (CABG) surgery. Off-pump CABG diminishes, but does not eliminate, the systemic inflammatory response and its influence on monocyte activation remains unclear. This study was performed to determine if off-pump CABG suppresses all features of monocyte activation. ⋯ Off-pump CABG surgery attenuates monocyte secreted cytokines and completely suppresses activation-dependent monocyte cell-surface changes (CD11b, monocyte-platelet conjugate formation). Whether these pathophysiologic differences in monocyte activation translate into a reduction in adverse events after CABG surgery warrants a larger, randomized, outcomes study.
-
J. Cardiothorac. Vasc. Anesth. · Jun 2008
Comparative StudyThe accuracy of the Vigileo/FloTrac continuous cardiac output monitor.
The Vigileo/FloTrac system (software version 1.01; Edwards Lifesciences, Irvine, CA) determines cardiac output, without calibration, by analysis of the arterial pulse wave. To assess the accuracy of the Vigileo/FloTrac system, it was compared with the pulmonary artery catheter bolus thermodilution method as the current standard method. The study design was prospective and observer blinded. ⋯ The described deviation from the standard must be regarded according to the user's needs. Considering the 30% limits of agreement, the Vigileo system (version 1.01) seems sufficiently accurate; applying the 20% criteria, it is not.